TransMedics Group, Inc. (TMDX)
TransMedics Group, Inc. (TMDX) All Metrics
TMDX Valuation Metrics
TMDX Stock Price Metrics
Last Close Price$78.791-Day Change+7.61%Market Cap (USD)$2.723B7D Return8.06%30D Return14.44%YTD Return(35.78%)52-Week High$156.0052-Week High Date12/01/2025Current vs High(49.49%)52-Week Low$60.1052-Week Low Date05/14/2026Current vs Low31.09%Avg Volume 1M1.313MBeta1.88Fair Value Price-Margin of Safety-
TMDX Dividend Metrics
TMDX Growth Rate Metrics
Price CAGR TTM(36.48%)Price CAGR 3Y0.07%Price CAGR 5Y21.48%Total Return CAGR TTM(36.48%)Total Return CAGR 3Y0.07%Total Return CAGR 5Y21.48%Revenue CAGR TTM30.24%Revenue CAGR 3Y74.74%Revenue CAGR 5Y90.79%Net Income CAGR TTM251.23%Net Income CAGR 3Y-Net Income CAGR 5Y-EPS CAGR TTM423.96%EPS CAGR 3Y-EPS CAGR 5Y-FCF CAGR TTM-FCF CAGR 3Y-FCF CAGR 5Y-Dividends CAGR TTM-Dividends CAGR 3Y-Dividends CAGR 5Y-
TMDX Discounted Cash Flow Metrics
| Fair Value Price | - |
| Margin of Safety | - |
TMDX Revenue Metrics
TMDX PE Ratio Metrics
| PE Ratio | 18.03 |
| PE Ratio Avg TTM | 48.69 |
| PE Ratio Avg 3Y | 60.67 |
| Current VS TTM Avg | -62.97% |
| Current VS 3Y Avg | -70.28% |
| Current VS 5Y Avg | -70.28% |
TMDX PS Ratio Metrics
| PS Ratio | 4.48 |
| PS Ratio Avg TTM | 9.00 |
| PS Ratio Avg 3Y | 10.54 |
| Current VS TTM Avg | -50.21% |
| Current VS 3Y Avg | -57.51% |
| Current VS 5Y Avg | -72.43% |
TMDX PB Ratio Metrics
| PB Ratio | 5.77 |
| PB Ratio Avg TTM | 13.16 |
| PB Ratio Avg 3Y | 16.94 |
| Current VS TTM Avg | -56.15% |
| Current VS 3Y Avg | -65.95% |
| Current VS 5Y Avg | -61.13% |
TMDX Price to Free Cash Flow Ratio Metrics
| PFCF Ratio | 18.84 |
| PFCF Ratio Avg TTM | 104.61 |
| PFCF Ratio Avg 3Y | 104.61 |
| Current VS TTM Avg | -81.99% |
| Current VS 3Y Avg | -81.99% |
| Current VS 5Y Avg | -81.99% |
TMDX Debt to Equity Ratio Metrics
| Debt/Equity Ratio | 0.99 |
| Debt/Equity Ratio Avg TTM | 1.63 |
| Debt/Equity Ratio Avg 3Y | 1.85 |
| Current VS TTM Avg | -39.26% |
| Current VS 3Y Avg | -46.34% |
| Current VS 5Y Avg | -28.95% |
TMDX PEG Ratio Metrics
| PEG Ratio | 0.05 |
| PEG Ratio Avg TTM | - |
| PEG Ratio Avg 3Y | 1.66 |
| Current VS TTM Avg | - |
| Current VS 3Y Avg | -96.98% |
| Current VS 5Y Avg | -96.23% |
TMDX FCF Yield
| FCF Yield | 5.31% |
| FCF Yield Avg TTM | 2.34% |
| FCF Yield Avg 3Y | 2.34% |
| Current VS TTM Avg | +127.34% |
| Current VS 3Y Avg | +127.34% |
| Current VS 5Y Avg | +127.34% |
TMDX Earnings Yield
| Earnings Yield | 5.55% |
| Earnings Yield Avg TTM | 2.75% |
| Earnings Yield Avg 3Y | 1.25% |
| Current VS TTM Avg | +101.65% |
| Current VS 3Y Avg | +343.02% |
| Current VS 5Y Avg | +343.02% |
TMDX EV/EBIT Ratio Metrics
| Ev/Ebit Ratio | 34.45 |
| Ev/Ebit Ratio Avg TTM | 53.99 |
| Ev/Ebit Ratio Avg 3Y | 68.54 |
| Current VS TTM Avg | -36.19% |
| Current VS 3Y Avg | -49.74% |
| Current VS 5Y Avg | -49.74% |
TMDX EV/EBITDA Ratio Metrics
| Ev/Ebitda Ratio | 23.28 |
| Ev/Ebitda Ratio Avg TTM | 38.80 |
| Ev/Ebitda Ratio Avg 3Y | 41.75 |
| Current VS TTM Avg | -40.00% |
| Current VS 3Y Avg | -44.24% |
| Current VS 5Y Avg | -44.24% |
TMDX EV/Assets Ratio Metrics
| Ev/Assets Ratio | 2.27 |
| Ev/Assets Ratio Avg TTM | 5.39 |
| Ev/Assets Ratio Avg 3Y | 4.92 |
| Current VS TTM Avg | -57.89% |
| Current VS 3Y Avg | -53.82% |
| Current VS 5Y Avg | -58.55% |
TMDX EV/Sales Ratio Metrics
| Ev/Sales Ratio | 5.12 |
| Ev/Sales Ratio Avg TTM | 9.04 |
| Ev/Sales Ratio Avg 3Y | 10.89 |
| Current VS TTM Avg | -43.33% |
| Current VS 3Y Avg | -53.00% |
| Current VS 5Y Avg | -68.63% |
TMDX Current Ratio Metrics
| Current Ratio | 7.14 |
| Current Ratio Avg TTM | 7.72 |
| Current Ratio Avg 3Y | 8.85 |
| Current VS TTM Avg | -7.51% |
| Current VS 3Y Avg | -19.32% |
| Current VS 5Y Avg | -18.97% |
TMDX Quick Ratio Metrics
| Quick Ratio | 6.59 |
| Quick Ratio Avg TTM | 7.05 |
| Quick Ratio Avg 3Y | 8.10 |
| Current VS TTM Avg | -6.59% |
| Current VS 3Y Avg | -18.62% |
| Current VS 5Y Avg | -17.98% |
TMDX ROIC Metrics
| ROIC | 10.94% |
| ROIC Avg 3Y | (0.14%) |
| ROIC Avg 5Y | (9.11%) |
| Current VS 3Y Avg | -8203.70% |
| Current VS 5Y Avg | -220.04% |
| Current VS 10Y Avg | -139.54% |
TMDX Return on Assets Metrics
| ROA | 17.81 |
| ROA Avg TTM | 11.11 |
| ROA Avg 3Y | 1.40 |
| Current VS TTM Avg | +60.31% |
| Current VS 3Y Avg | +1169.88% |
| Current VS 5Y Avg | -331.90% |
TMDX Return on Equity Metrics
| ROE | 40.22 |
| ROE Avg TTM | 27.86 |
| ROE Avg 3Y | 4.54 |
| Current VS TTM Avg | +44.34% |
| Current VS 3Y Avg | +786.39% |
| Current VS 5Y Avg | -423.14% |
TMDX Net Profit Margin Metrics
| Net Profit Margin | 31.43% |
| Net Profit Margin Avg TTM | 19.73% |
| Net Profit Margin Avg 3Y | (2.42%) |
| Current VS TTM Avg | +59.30% |
| Current VS 3Y Avg | -1400.10% |
| Current VS 5Y Avg | -170.39% |
Last Updated: Saturday, June 20, 2026
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein